Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer.

Palka, Magda; Sanchez, Antonio; Córdoba, Mar; Nuevo, Gema Díaz; De Ugarte, Andrés Varela; Cantos, Blanca; Méndez, Miriam; Calvo, Virginia; Maximiano, Constanza; Provencio, Mariano

Palka, Magda; Sanchez, Antonio; Córdoba, Mar; Nuevo, Gema Díaz; De Ugarte, Andrés Varela; Cantos, Blanca; Méndez, Miriam; Calvo, Virginia; Maximiano, Constanza; Provencio, Mariano.

Afiliación

Palka M; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Sanchez A; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Córdoba M; Department of Thoracic Surgery, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Nuevo GD; Department of Pneumology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
De Ugarte AV; Department of Thoracic Surgery, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Cantos B; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Méndez M; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Calvo V; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Maximiano C; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.
Provencio M; Department of Clinical Oncology, Puerta de Hierro Hospital, 28222 Madrid, Spain.

Oncol Lett ; 13(3): 1647-1654, 2017 Mar.

Article en En | MEDLINE | ID: mdl-28454304

Palabras clave

cisplatin; induction treatment; neoadjuvant chemotherapy; stage III non-small cell lung cancer; survival; vinorelbine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncol Lett Año: 2017 Tipo del documento: Article País de afiliación: España

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google